The report "Vaccine
Adjuvants Market by Product (Particulate, Emulsions, Pathogen, Saponin),
Route of Administration (Subcutaneous, Intramuscular), Disease Type
(Infectious, Cancer), Application (Research, Commercial) & Application
Category - Global Forecast to 2027", is projected to reach USD 1.6
billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 1.7% during the
forecast period of 2022 to 2027.
Get a Sample PDF of report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894
Vaccine adjuvants are substances that are added to a vaccine
in order to boost its effectiveness. Vaccine adjuvants have the ability to
modulate the immune response to the vaccine, and they are used in many vaccines
to increase the body’s immune response to the antigen. The global vaccine
adjuvants market is expected to grow significantly in the near future due to
its increasing use in vaccines, rising demand for effective vaccines,
increasing prevalence of infectious diseases, and increasing funding for vaccine
research and development.
The increasing prevalence of infectious diseases is a major
factor driving the growth of the vaccine adjuvants market. Vaccines are used to
prevent the spread of infectious diseases, and adjuvants are used to boost the
effectiveness of vaccines. As the prevalence of infectious diseases increases,
the demand for effective vaccines also increases, resulting in an increased
demand for vaccine adjuvants.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894
Key
Market Players
The global vaccine adjuvants market is highly competitive. The prominent
players operating in this market include GSK plc (UK), Dynavax Technologies
(US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic
(France), OZ Biosciences (US), Phibro Animal Health Corporation (US),
Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL
Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH
(Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South
Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), Vaxine Pty
Ltd. (Australia), Creative Diagnostics (US), LiteVax BV (Netherlands), Mukta
Industries (India), Oncovir, Inc. (US), and TiterMax USA, Inc. (US).
GSK plc (UK)
GlaxoSmithKline (UK) held the leading position in the market. The
company has entered into collaborations and partnerships with a number of
vaccine developers and is recognized for its contrition in the COVID-19 space.
SK Bioscience (South Korea), Bharat Biotech International Limited (India), and
Government of Canada (Canada) are some of the major partners of the company.
Dynavax Technologies (US)
In 2021, Dynavax focuses on inorganic growth strategies to maintain its
market position. Biological E Limited (India), Clover Biopharmaceuticals
(China), Valneva SE (France), and Medigen Vaccine Biologics (China) are some of
the company’s partners in vaccine development.
Novavax (US)
Novavax is also one of the leading players in the vaccine adjuvants
market. The company focuses on inorganic growth strategies such as partnerships
to strengthen its market position. The company partnered with AGC Biologics
(Denmark) and Serum Institute of India (India) for the development of vaccines
for COVID-19 and malaria.
The Asia Pacific region is the fastest-growing region of
the vaccine adjuvants market.
The Asia Pacific is estimated to be the fastest-growing segment
of the market. The growth of the vaccine adjuvants markets of the region is
drive by increasing investments in the life sciences sector and rising
awareness through conferences & symposiums, and growing emphasis on
strategic initiatives such as partnerships, and collaborations by biopharma and
biotech companies.
Recent Developments
·
Dynavax Technologies (US) entered into a fully
funded collaboration with the US Department of Defense to conduct a Phase 2
clinical trial for a plague vaccine adjuvanted with CpG 1018.
·
SK Bioscience (South Korea)and GSK plc
(UK)entered into a collaboration for COVID-19 vaccine development.
Direct Purchase Vaccine Adjuvants Market Research Report
Now @ https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=152603894
About MarketsandMarkets™
MarketsandMarkets™ is a blue ocean alternative in growth
consulting and program management, leveraging a man-machine offering to drive
supernormal growth for progressive organizations in the B2B space. We have the
widest lens on emerging technologies, making us proficient in co-creating
supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion
of new revenue streams that are substituting existing revenue streams in this
decade alone. We work with clients on growth programs, helping them monetize
this $25 trillion opportunity through our service lines - TAM Expansion,
Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account
Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several
Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive
ecosystem. Our insights and strategies are molded by our industry experts,
cutting-edge AI-powered Market Intelligence Cloud, and years of research. The
KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates
an analysis of interconnections through a set of applications, helping clients
look at the entire ecosystem and understand the revenue shifts happening in
their industry.
To find out more, visit www.MarketsandMarkets™.com or follow
us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
